Alexion Pharmaceuticals, Inc.

Robbins Arroyo LLP Is Investigating the Officers and Directors of Alexion Pharmaceuticals, Inc. (ALXN) on Behalf of Shareholders

Robbins Arroyo LLP is investigating whether certain officers and directors of Alexion Pharmaceuticals, Inc. (NASDAQGS: ALXN) breached their fiduciary duties to shareholders. Alexion, a biopharmaceutical company, develops and commercializes life-transforming therapeutic products.

Alexion’s Top Executives Step Down

Alexion disclosed in November 2016 that the company was investigating allegations made by a former employee regarding improper sales practices with respect to its flagship drug, Soliris. Alexion’s Chief Executive Officer, David Hallal, and Chief Financial Officer, Vikas Sinha, recently left their roles at the company amid the internal investigation. A Cowen analyst wrote to investors, “We now believe the board lost confidence in its senior leadership team, perhaps due to findings of unprofessional activity that were uncovered during the investigation, and decided that a change needed to be made now.” On this news, Alexion’s stock fell, closing at $110.01 per share on December 13, 2016. The company, which delayed the filing of its most recent performance report due to the investigation, expects to file it in January.

Alexion Shareholders Have Legal Options

Concerned shareholders who would like more information about their rights and potential remedies can contact attorney Darnell R. Donahue at (800) 350-6003, or you can complete the form below and we will contact you directly.

 

Shareholder Information

Items marked with an asterisk (*) are required information.

First Name * Last Name *
Phone *
E-mail * Confirm: E-mail *
Number of Shares Owned:
Comments:

Please Note: Neither the submission to nor the receipt of information by Robbins Arroyo LLP or one of its attorneys through this website constitutes an agreement by our firm to represent the individual and does not create an attorney-client relationship. Please do not send confidential or sensitive information through this website. This information should be communicated through a direct contact with an individual at the firm.

* I have read the disclaimer information
+=

    Send This Post

    Tags: